The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Jesudian AB, de Jong YP, Jacobson IM. Clin Gastroenterol Hepatol. 2013 Apr 11. pii: S1542-3565(13)00457-6. doi: 10.1016/j.cgh.2013.04.003. [Epub ahead of print]
Source
Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York.
Abstract
Therapy for hepatitis C virus (HCV) is a rapidly evolving field wherein traditional treatment with the nonspecific antiviral agents pegylated interferon (IFN)-alfa and ribavirin has been and will continue to be supplanted by combinations of targeted therapies against HCV with and without concomitant pegylated IFN and/or ribavirin, resulting in markedly superior rates of viral clearance. Exhaustive study of HCV structure and replication through the development of in vitro systems have enabled the development of numerous novel direct acting antiviral agents that currently are undergoing clinical trials. As our understanding of the HCV virus and its antiviral targets increases, the future of HCV therapy holds the promise of high rates of viral eradication in all patient populations, many or all of whom will be treatable with IFN-free combinations of all-oral agents.